332 related articles for article (PubMed ID: 27699881)
1. Structural basis of reversine selectivity in inhibiting Mps1 more potently than aurora B kinase.
Hiruma Y; Koch A; Dharadhar S; Joosten RP; Perrakis A
Proteins; 2016 Dec; 84(12):1761-1766. PubMed ID: 27699881
[TBL] [Abstract][Full Text] [Related]
2. Understanding inhibitor resistance in Mps1 kinase through novel biophysical assays and structures.
Hiruma Y; Koch A; Hazraty N; Tsakou F; Medema RH; Joosten RP; Perrakis A
J Biol Chem; 2017 Sep; 292(35):14496-14504. PubMed ID: 28726638
[TBL] [Abstract][Full Text] [Related]
3. Insights into Resistance Mechanisms of Inhibitors to Mps1 C604Y Mutation via a Comprehensive Molecular Modeling Study.
Chen Y; Yu W; Jiang CC; Zheng JG
Molecules; 2018 Jun; 23(6):. PubMed ID: 29925769
[TBL] [Abstract][Full Text] [Related]
4. Preferential killing of p53-deficient cancer cells by reversine.
Jemaà M; Galluzzi L; Kepp O; Boilève A; Lissa D; Senovilla L; Harper F; Pierron G; Berardinelli F; Antoccia A; Castedo M; Vitale I; Kroemer G
Cell Cycle; 2012 Jun; 11(11):2149-58. PubMed ID: 22592527
[TBL] [Abstract][Full Text] [Related]
5. A TPR domain-containing N-terminal module of MPS1 is required for its kinetochore localization by Aurora B.
Nijenhuis W; von Castelmur E; Littler D; De Marco V; Tromer E; Vleugel M; van Osch MH; Snel B; Perrakis A; Kops GJ
J Cell Biol; 2013 Apr; 201(2):217-31. PubMed ID: 23569217
[TBL] [Abstract][Full Text] [Related]
6. Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells.
D'Alise AM; Amabile G; Iovino M; Di Giorgio FP; Bartiromo M; Sessa F; Villa F; Musacchio A; Cortese R
Mol Cancer Ther; 2008 May; 7(5):1140-9. PubMed ID: 18483302
[TBL] [Abstract][Full Text] [Related]
7. Dissecting the role of MPS1 in chromosome biorientation and the spindle checkpoint through the small molecule inhibitor reversine.
Santaguida S; Tighe A; D'Alise AM; Taylor SS; Musacchio A
J Cell Biol; 2010 Jul; 190(1):73-87. PubMed ID: 20624901
[TBL] [Abstract][Full Text] [Related]
8. Identification of the hot spot residues for pyridine derivative inhibitor CCT251455 and ATP substrate binding on monopolar spindle 1 (MPS1) kinase by molecular dynamic simulation.
Chen K; Duan W; Han Q; Sun X; Li W; Hu S; Wan J; Wu J; Ge Y; Liu D
J Biomol Struct Dyn; 2019 Feb; 37(3):611-622. PubMed ID: 29380674
[TBL] [Abstract][Full Text] [Related]
9. TC Mps1 12, a novel Mps1 inhibitor, suppresses the growth of hepatocellular carcinoma cells via the accumulation of chromosomal instability.
Choi M; Min YH; Pyo J; Lee CW; Jang CY; Kim JE
Br J Pharmacol; 2017 Jun; 174(12):1810-1825. PubMed ID: 28299790
[TBL] [Abstract][Full Text] [Related]
10. Novel Mps1 kinase inhibitors: from purine to pyrrolopyrimidine and quinazoline leads.
Bursavich MG; Dastrup D; Shenderovich M; Yager KM; Cimbora DM; Williams B; Kumar DV
Bioorg Med Chem Lett; 2013 Dec; 23(24):6829-33. PubMed ID: 24183538
[TBL] [Abstract][Full Text] [Related]
11. Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition.
Jemaà M; Manic G; Lledo G; Lissa D; Reynes C; Morin N; Chibon F; Sistigu A; Castedo M; Vitale I; Kroemer G; Abrieu A
Oncotarget; 2016 Jan; 7(1):885-901. PubMed ID: 26637805
[TBL] [Abstract][Full Text] [Related]
12. Studies of Interaction Mechanism between Pyrido [3,4-
Xing C; Zhou X; Chen C; Sun W; Zheng Q; Liang D
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443663
[TBL] [Abstract][Full Text] [Related]
13. A crystal structure of the human protein kinase Mps1 reveals an ordered conformation of the activation loop.
Roorda JC; Joosten RP; Perrakis A; Hiruma Y
Proteins; 2019 Apr; 87(4):348-352. PubMed ID: 30582207
[TBL] [Abstract][Full Text] [Related]
14. Dynamic localization of Mps1 kinase to kinetochores is essential for accurate spindle microtubule attachment.
Dou Z; Liu X; Wang W; Zhu T; Wang X; Xu L; Abrieu A; Fu C; Hill DL; Yao X
Proc Natl Acad Sci U S A; 2015 Aug; 112(33):E4546-55. PubMed ID: 26240331
[TBL] [Abstract][Full Text] [Related]
15. Biophysical and X-ray crystallographic analysis of Mps1 kinase inhibitor complexes.
Chu ML; Lang Z; Chavas LM; Neres J; Fedorova OS; Tabernero L; Cherry M; Williams DH; Douglas KT; Eyers PA
Biochemistry; 2010 Mar; 49(8):1689-701. PubMed ID: 20099905
[TBL] [Abstract][Full Text] [Related]
16. Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective.
Wang S; Zhang M; Liang D; Sun W; Zhang C; Jiang M; Liu J; Li J; Li C; Yang X; Zhou X
Eur J Med Chem; 2019 Aug; 175():247-268. PubMed ID: 31121430
[TBL] [Abstract][Full Text] [Related]
17. Molecular basis underlying resistance to Mps1/TTK inhibitors.
Koch A; Maia A; Janssen A; Medema RH
Oncogene; 2016 May; 35(19):2518-28. PubMed ID: 26364596
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.
Laufer R; Li SW; Liu Y; Ng G; Lang Y; Feher M; Brokx R; Beletskaya I; Hodgson R; Mao G; Plotnikova O; Awrey DE; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
Bioorg Med Chem Lett; 2016 Aug; 26(15):3562-6. PubMed ID: 27335255
[TBL] [Abstract][Full Text] [Related]
19. A unique hinge binder of extremely selective aminopyridine-based Mps1 (TTK) kinase inhibitors with cellular activity.
Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Kojima E; Mitsuoka Y; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Yoshizawa H; Murai H; Nakamura Y
Bioorg Med Chem; 2015 May; 23(9):2247-60. PubMed ID: 25801152
[TBL] [Abstract][Full Text] [Related]
20. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.
Mason JM; Wei X; Fletcher GC; Kiarash R; Brokx R; Hodgson R; Beletskaya I; Bray MR; Mak TW
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3127-3132. PubMed ID: 28270606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
